Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors

Investigational New Drugs

Volumn 26, Issue 5, 2008, Pages 455-462

  LoRusso, Patricia ^a   Heath, Elisabeth I ^a   McGreivy, Jesse ^b   Sun, Yu Nien ^b   Melara, Rebeca ^b   Yan, Lucy ^b   Malburg, Lisa ^a   Ingram, Megan ^b   Wiezorek, Jeffrey ^b   Chen, Li ^b   Pilat, Mary Jo ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

^b AMGEN INC   (United States)

Author keywords

CYP3A4 inhibitor; Ketoconazole; Motesanib diphosphate; Pharmacokinetics; Phase I study; Solid tumors; Tolerability

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOCHROME P450 3A4; KETOCONAZOLE; MOTESANIB DIPHOSPHATE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEMOPTYSIS; HUMAN; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID TUMOR; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING;

AGED; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KETOCONAZOLE; MALE; MIDDLE AGED; NEOPLASMS; NIACINAMIDE;

EID: 50249158488     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9144-1     Document Type: Article

References (33)

1. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature 407 249 257
2. P Carmeliet 2000 Mechanisms of angiogenesis and arteriogenesis Nat Med 6 389 395
3. J Matsui T Wakabayashi M Asada K Yoshimatsu M Okada 2004 Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells J Biol Chem 279 18600 18607
4. W Zhang G Stoica SI Tasca KA Kelly CJ Meininger 2000 Modulation of tumor angiogenesis by stem cell factor Cancer Res 60 6757 6762
5. A Polverino A Coxon C Starnes Z Diaz T Demelfi L Wang J Bready J Estrada R Cattley S Kaufman D Chen Y Gan G Kumar J Meyer S Neervannan G Alva J Talvenheimo S Montestruque A Tasker V Patel R Radinsky R Kendall 2006 AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Res 66 8715 8721
6. FA Scappaticci 2002 Mechanisms and future directions for angiogenesis-based cancer therapies J Clin Oncol 20 3906 3927
7. K Mross J Drevs M Muller M Medinger D Marme J Hennig B Morgan D Lebwohl E Masson YY Ho C Gunther D Laurent C Unger 2005 Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours Eur J Cancer 41 1291 1299
8. AL Thomas B Morgan MA Horsfield A Higginson A Kay L Lee E Masson M Puccio-Pick D Laurent WP Steward 2005 Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer J Clin Oncol 23 4162 4171
9. GD Demetri AT van Oosterom CR Garrett ME Blackstein MH Shah J Verweij G McArthur IR Judson MC Heinrich JA Morgan J Desai CD Fletcher S George CL Bello X Huang CM Baum PG Casali 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338
10. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134
11. EE Cohen EE Vokes LS Rosen MS Kies AA Forastiere FP Worden MA Kane KF Liau DR Shalinsky RB Cohen 2007 A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers J Clin Oncol 25 6008
12. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342
13. RA Burger MW Sill BJ Monk BE Greer JI Sorosky 2007 Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 5165 5171
14. SA Cannistra UA Matulonis RT Penson J Hambleton J Dupont H Mackey J Douglas RA Burger D Armstrong R Wenham W McGuire 2007 Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 5180 5186
15. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati R Lilenbaum DH Johnson 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550
16. LS Rosen R Kurzrock M Mulay A Van Vugt M Purdom C Ng J Silverman A Koutsoukos YN Sun MB Bass RY Xu A Polverino JS Wiezorek DD Chang R Benjamin RS Herbst 2007 Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors J Clin Oncol 25 2369 2376
17. Indiana University School of Medicine (2007) Drug interaction table (cytochrome P450 system). Available at: http://medicine.iupui.edu/flockhart/ table.htm. Accessed 31 May 2007
18. LL von Moltke DJ Greenblatt J Schmider SX Duan CE Wright JS Harmatz RI Shader 1996 Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents J Clin Pharmacol 36 783 791
19. TD Bjornsson JT Callaghan HJ Einolf V Fischer L Gan S Grimm J Kao SP King G Miwa L Ni G Kumar J McLeod RS Obach S Roberts A Roe A Shah F Snikeris JT Sullivan D Tweedie JM Vega J Walsh SA Wrighton 2003 The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective Drug Metab Dispos 31 815 832
20. TK Daneshmend DW Warnock 1988 Clinical pharmacokinetics of ketoconazole Clin Pharmacokinet 14 13 34
21. SM Tsunoda RL Velez LL von Moltke DJ Greenblatt 1999 Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole Clin Pharmacol Ther 66 461 471
22. A Varhe KT Olkkola PJ Neuvonen 1994 Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole Clin Pharmacol Ther 56 601 607
23. H Boxenbaum 1999 Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general J Pharm Pharm Sci 2 47 52
24. C Dutreix B Peng G Mehring M Hayes R Capdeville R Pokorny M Seiberling 2004 Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects Cancer Chemother Pharmacol 54 290 294
25. C Lathia J Lettieri F Cihon M Gallentine M Radtke P Sundaresan 2006 Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics Cancer Chemother Pharmacol 57 685 692
26. Pfizer (2007) Sunitinib malate (Sutent®) prescribing information. Available at: www.sutent.com. Accessed 11 October 2007
27. LS Schwartzberg J Stephenson D Kotasek D Goldstein N Tebbutt J McGreivy Y Sun L Yang H Burris 2007 Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) J Clin Oncol 25 4081
28. TJ Price J Williams J McGreivy S McCoy Y Sun B Aguero-O'Neill M Rosenthal 2007 Safety and pharmacokinetics (PK) of AMG 706 in combination with gemcitabine for the treatment of patients (pts) with solid tumors J Clin Oncol 25 14005
29. Genentech (2008) Bevacizumab (Avastin®) prescribing information. Available at: www.avastin.com. Accessed 11 October 2007
30. FA Eskens J Verweij 2006 The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review Eur J Cancer 42 3127 3139
31. HS Rugo RS Herbst G Liu JW Park MS Kies HM Steinfeldt YK Pithavala SD Reich JL Freddo G Wilding 2005 Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 5474 5483
32. S Faivre C Delbaldo K Vera C Robert S Lozahic N Lassau C Bello S Deprimo N Brega G Massimini JP Armand P Scigalla E Raymond 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25 35
33. SE Al-Batran A Atmaca E Schleyer C Pauligk C Hosius G Ehninger E Jager 2007 Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer-a dose-escalation Phase I trial Cancer 109 1897 1904